BioMérieux

BioMérieux

Provides diagnostic solutions which determine the source of disease and contamination to improve patient health and ensure consumer safety. Learn more

Launch date
Employees
Market cap
CAD19.5b
Enterprise valuation
CAD19.9b (Public information from Sep 2024)
Marcy-l'Étoile Auvergne-Rhône-Alpes (HQ)

Financials

Estimates*

Edit
Revenues, earnings & profits over time
EUR2019202020212022202320242025
Revenues2.7b3.1b3.4b3.6b3.7b3.5b3.8b
% growth-17 %8 %6 %2 %(4 %)7 %
EBITDA579m809m1.0b943m828m--
% EBITDA margin22 %26 %31 %26 %23 %--
Profit273m404m601m452m358m--
% profit margin10 %13 %18 %13 %10 %--
R&D budget374m399m389m447m460m--
R&D % of revenue14 %13 %12 %12 %13 %--
  • Edit
DateInvestorsAmountRound
-

N/A

-
*
N/A

N/A

IPO
Total Funding-

Recent News about BioMérieux

Edit
More about BioMérieuxinfo icon
Edit

bioMérieux is a global leader in the field of in vitro diagnostics, specializing in innovative solutions to combat infectious diseases and antimicrobial resistance. The company serves healthcare providers, laboratories, and public health organizations worldwide. Operating in the medical diagnostics market, bioMérieux's business model revolves around the development, manufacturing, and distribution of diagnostic tests and systems. These products help detect and manage infectious diseases, ensuring timely and accurate diagnosis, which is crucial for effective treatment. Revenue is generated through the sale of diagnostic instruments, reagents, and software solutions, as well as through service contracts and partnerships. The company is committed to public health and leverages its expertise to address global health challenges, including the growing threat of antimicrobial resistance.

Keywords: in vitro diagnostics, infectious diseases, antimicrobial resistance, healthcare, laboratories, diagnostic tests, medical diagnostics, public health, diagnostic instruments, reagents.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Investments analysisEdit
  • Edit
Astute Medical
ACQUISITION by BioMérieux Apr 2018
Invisible Sentinel
ACQUISITION by BioMérieux Feb 2019
PML Microbiologicals
ACQUISITION by BioMérieux Dec 2008
AdvanDx
ACQUISITION by OpGen Jul 2015
Hyglos
ACQUISITION by BioMérieux Jun 2016
BioFire Diagnostics
ACQUISITION by BioMérieux Jan 2014
Applied Maths N.V.
ACQUISITION by BioMérieux Jan 2016
Bacterial Barcodes
ACQUISITION by BioMérieux Sep 2006
View 19 more